SCHEMBL2889257

SCHEMBL2889257

CCOC(=O)c1nc(Cc2ccc3c(c2)OCO3)c2[nH]c(-c3ccc(Cl)cc3)c(C)c2c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
KDM4E B2RXH2 4/20 0.48
HSD17B10 Q99714 4/20 0.48
TP53 P04637 2/20 0.48
CFTR P13569 1/20 0.41
CYP19A1 P11511 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
HTT P42858 2/20 0.40
TSHR P16473 2/20 0.40
PKM P14618 1/20 0.40
TARBP2 Q15633 1/20 0.40
ALDH1A1 P00352 6/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 4/20 0.40
HPGD P15428 3/20 0.40
ALOX15 P16050 2/20 0.40
ALOX5 P09917 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887140 0.92 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2886805 0.87 SMN1; SMN2 (0.44) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2881939 0.86 EGLN1 (0.45) SMN1; SMN2KDM4EHSD17B10TP53HTT
SCHEMBL2886873 0.85 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2887810 0.81 KDM4E (0.42) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2881212 0.76 EGLN1 (0.41) SMN1; SMN2KDM4EHSD17B10TP53HTT
SCHEMBL2887962 0.76 HSD17B10 (0.48) SMN1; SMN2KDM4EHSD17B10TP53CYP19A1
SCHEMBL2889330 0.76 KDM4E (0.44) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2889255 0.71 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EHSD17B10TP53CFTR
SCHEMBL2881025 0.68 EGLN1 (0.43) SMN1; SMN2KDM4EHSD17B10TP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 SMN1; SMN2 3919/4885KDM4E 754/4885HSD17B10 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.